

GRIFOLS CORPORATE STATEMENT ON THE NOVEL CORONAVIRUS

March 13, 2020

Employee safety is our priority

Following the World Health Organization (WHO) declaring the coronavirus outbreak a pandemic, Grifols is taking additional measures to help protect our employees. The company continues to make all its technical knowledge and expertise in plasma and diagnostics available to health authorities during these exceptional circumstances.

The restriction on international travel, in place since February 24, has been extended to domestic business trips as well. Grifols continues to encourage all business to be conducted through video conferencing and other technologies. In addition, the company has implemented a work-from-home policy and is also limiting external visits to Grifols sites and production plants.

Ensuring product supply and safety

Aware that our medicines are critical for patients and healthcare providers around the world, the company continues to work to ensure that our products reach those who need them. Currently we can confirm there are no supply delays or interruptions.

Every single donation at Grifols goes through exhaustive tests and analyses to ensure it meets our strict requirements. However, out of an abundance of caution, we are implementing additional protocols and measures. Furthermore, our plasma product manufacturing process contains dedicated steps for viral inactivation that ensure high safety margins against this type of virus.

Given the exceptional circumstances, all relevant knowledge matters

Since the beginning of the epidemic, Grifols has shared its broad knowledge and technology in convalescent plasma (plasma with antibodies against the virus) with our partner-to-be in China, Shanghai RAAS, and international health authorities to develop a potential antiviral treatment with immunoglobulins. At the same time, Grifols is accelerating the development of diagnostic and screening tests for the detection of the novel coronavirus.

Grifols continues to evaluate the evolution of the coronavirus and to update protocols, taking the necessary measures in accordance with recommendations from local, regional and national governments. Furthermore, we will continue to take actions, in consultation with recommendations from health authorities and regulatory agencies, to protect our employees, ensure our products reach those patients who need them, and do what we can to help combat the coronavirus.

For additional information, please see the [statement](#) from the Plasma Protein Therapeutics Association (PPTA).

GRIFOLS